DV
Dividend Vision

GENE — Genetic Technologies Ltd

Genetic Technologies Ltd (GENE)

Total return is 68.6% over the past 20.9 years, 754.2 points behind SPY at 822.8%. Its deepest 1-year drawdown was 6.8%.

GENE is an equity stock fund established in 2005 that focuses on genetic technologies and related sectors within the broader biotechnology and life sciences industry. The fund provides exposure to companies involved in genetic research, diagnostics, and therapeutic development. Limited data is available on distribution frequency, yield profile, and expense ratio, making this suitable primarily for investors seeking growth-oriented equity exposure to the genetics and biotechnology space rather than those focused on current income generation.

GENE key facts

Asset type
Stock
Asset class
Equity
Inception date
09/06/2005
Last close
$2,023.50
Market cap
$3,708,138
Average volume
154.0
Payment date
08/15/2019
Beta
0.48
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.02